DanDrit Biotech A/S to Present at the 8th Annual European Life Sciences CEO Forum, March 3rd and 4th

COPENHAGEN, Denmark, Feb. 24, 2015 /PRNewswire/ -- DanDrit Biotech A/S ("DanDrit Denmark") (OTC: DDRT), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, announced that its Chief Executive Officer, Dr. Eric Leire, will be speaking at the 8^th Annual European Life Sciences CEO Forum in Zurich Switzerland at the Hilton Airport Hotel, March 3-4.

Dr. Leire noted, "This is an excellent opportunity to introduce the exciting developments ongoing at DanDrit as we pursue the development of our lead compound MCV, a colorectal cancer immunotherapy. Our proprietary and patented approach using a patient's own blood to develop a vaccine shows great promise and we will be making several announcements shortly discussing our continuing success."

About DanDrit

We are a biotechnology company focusing on VIVA a Phase III clinical trial for our lead compound MCV.  MCV is an adjuvant immunotherapy that intends to prevent colon cancer recurrence after standard of care surgery and chemotherapy. Our expertise in producing dendritic cells from a patient's blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.

Visit us at our website: www.dandrit.com.

About 8th Annual European Life Sciences CEO Forum

The 8th Annual European Life Sciences CEO Forum & Exhibition, is being held on 3rd-4th March 2015 at the Hilton Zurich Airport Hotel, Switzerland. This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. We expect around 350 delegates and 80 presenting companies.

Safe Harbor Statement

All statements in this release that are not based on historical fact are "forward looking statements". While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available at www.sec.gov.  Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Contact:

Wolfe Axelrod Weinberger Associates, LLC
Stephen D. Axelrod, CFA/Donald C. Weinberger
(212) 370-4500, (212) 370-4505 fax
[email protected], [email protected]

SOURCE DanDrit Biotech USA, Inc.

Related Links

http://www.dandrit.com